| Drug |
Study day |
AUC (µg/mL*h) |
Cmax (µg/mL) |
tmax (h) |
Cmin (µg/mL) |
tmin (h) |
| Rifampicin |
D 15 |
27.64 (13.19-39.77) |
5.05 (3.30-6.23) |
3.00 (2.00-4.00) |
0.0 (0.0-0.0) |
0.0 (0.0-0.0) |
| |
D 45 |
34.35 (22.39-58.19) |
5.05 (4.22-8.21) |
1.50 (1.00-2.00) |
0.0 (0.0-0.0) |
0.0 (0.0-0.0) |
| |
D90 |
34.39 (32.71-61.80) |
5.88 (5.81-8.50) |
2.00 (1.50-2.00) |
0.0 (0.0-0.0) |
0.0 (0.0-0.0) |
| |
D180 |
40.40 (37.84-58.26) |
6.51 (6.33-10.81) |
2.00 (2.00-4.00) |
0.0 (0.0-0.0) |
0.0 (0.0-0.0) |
| Lopinavir |
D 45 |
142.95 (112.88-168.85) |
14.71 (13.02-20.39) |
4.00 (3.50-4.50) |
4.64 (2.65-9.85) |
12.00 (0.00-12.00) |
| |
D90 |
179.38 (140.16-182.99) |
18.91 (16.37-21.16) |
4.00 (3.00-4.00) |
8.65 (4.33-10.01) |
1.00 (0.50-6.50) |
| |
D180* |
123.05 (88.47-154.56) |
16.65 (12.04-18.91) |
2.00 (1.50-2.00) |
0.74 (0.37-5.92) |
12.00 (12.00-12.00) |
| |
D180** |
173.95 (146.06-201.83) |
18.94 (15.86-22.03) |
5.00 (3.50-6.50) |
9.34 (7.60-11.07) |
11.00 (10.50-11.50) |
| |
D 210 |
119.14 (101.56-133.91) |
12.13 (10.58-14.18) |
4.00 (4.00-4.50) |
4.82 (3.25-6.16) |
6.00 (0.00-12.00) |
|
* median values of patients receiving LPV/r 800/200 mg
** median values of patients receiving LPV/r 600/150 mg |
| Table 3: Summary of the pharmacokinetic for rifampicin and lopinavir, by treatment stage (median, IQR). |
